IFT52

Across TCGA pan-cancer cohorts, IFT52 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IFT52 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IFT52 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFT52 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where IFT52 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.795	0.983	.013	43	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.075	.024	13	view →
LUAD	OS	Median	All	0.895	0.776	.011	13	view →
LSCC	DFS	Tertile	II,III,IV	0.863	1.000	.003	7	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
UCEC	OS	Quartile	All	0.847	1.000	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IFT52–HNSC (DFS)

Open the HNSC breakdown →